Эндокалцин

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Эндокалцин

What is Эндокалцин?

Эндокалцин (Endocalcin) is a pharmaceutical preparation of salmon calcitonin, a synthetic hormone that mimics the biological activity of the naturally occurring calcitonin produced by the thyroid gland. It belongs to a class of medications known as bone-resorption inhibitors, which play a significant role in regulating calcium levels and maintaining bone density.

Mechanism of Action

The primary function of Эндокалцин is to inhibit the activity of osteoclasts, the cells responsible for breaking down bone tissue. By slowing down bone resorption, the medication helps to:

  • Decrease the release of calcium from the bones into the bloodstream.
  • Promote the renal excretion of excess calcium, phosphate, and sodium.
  • Maintain a more stable bone structure in conditions characterized by rapid bone turnover.

Salmon calcitonin is used in medical practice because it is significantly more potent and has a longer duration of action compared to the human form of the hormone.

Clinical Applications

Эндокалцин is typically utilized in the management of metabolic bone diseases and conditions involving systemic calcium imbalances. Its clinical use is generally focused on the following areas:

  • Paget's Disease of Bone: A condition where the normal bone recycling process is disrupted, leading to fragile or misshapen bones.
  • Hypercalcemia: Assisting in the reduction of abnormally high calcium levels in the blood, often associated with oncology or endocrine disorders.
  • Bone Loss Prevention: Management of sudden bone loss due to acute immobilization.
  • Pain Management: In certain instances, it is used to alleviate bone pain associated with osteolysis or skeletal complications.

Composition and Delivery

As a peptide-based medication, Эндокалцин is highly sensitive to digestive enzymes and is therefore not administered orally. It is commonly supplied as a solution for injection or as a nasal spray, allowing the active ingredient to enter the bloodstream directly or through the nasal mucosa to ensure biological efficacy.

What side effects are possible with Эндокалцин?

Possible Side Effects and Safety Information

The safety profile of Calcitonin Salmon, as documented in official regulatory labels, outlines adverse reactions grouped by frequency and affected body systems. These classifications distinguish between expected, frequent events and rare, serious concerns. The drug is a polypeptide, and its official safety documentation addresses the possibility of systemic allergic reactions.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to the regulatory frequency framework (ICH/EMA):

Classification Examples of Reactions
Very Common Nausea, vomiting, and facial or upper body flushing (non-allergic vascular effect).
Common Dizziness, headache, diarrhea, musculoskeletal pain (including arthralgia and back pain), rhinitis, and epistaxis.
Uncommon Hypersensitivity reactions and visual disturbances.
Very Rare Serious allergic-type reactions, including anaphylactic shock.

System-Organ Classes and Specific Concerns

The officially documented side effects are categorized across several System-Organ Classes (SOC), including Gastrointestinal Disorders, Vascular Disorders, Nervous System Disorders, and Musculoskeletal and Connective Tissue Disorders.

Serious Adverse Reactions officially noted include anaphylactic shock and severe nasal ulceration (for the nasal spray form, requiring discontinuation if severe). Additionally, regulatory documents note an increased risk of malignancy associated with long-term use, prompting duration limitations by some authorities.

Nausea and vomiting are often more evident upon initiation of therapy and tend to diminish with continued use. The label also specifies that the drug is not generally indicated in pregnancy and that pre-existing hypocalcemia must be corrected before treatment begins.

Overdose and Emergency Response

The drug name Эндокалцин (Endocalcin) is not recognized within major public authoritative regulatory databases (e.g., FDA, EMA, Health Canada, TGA) that provide standardized drug safety information for widespread clinical use. As a result, specific official documentation detailing the signs, symptoms, required management, and emergency protocols for an overdose of this particular substance is not publicly available from these sources.

Overdose and Emergency Action

When a drug's official regulatory documentation is unavailable, general medical principles apply, and seeking immediate emergency medical help is critical following any suspected overdose or accidental ingestion of an unknown or excessive amount.

Urgent attention is required if:

  • An amount significantly larger than the prescribed dose was taken.
  • Any new, severe, or unexpected physiological changes, such as dizziness, confusion, seizures, or breathing difficulty, occur after ingestion.

In all cases of suspected overdose, medical professionals will need to be consulted immediately to determine the specific toxic risks, monitor vital signs, and initiate appropriate treatment, which may include supportive care or specific interventions based on the substance's pharmacological properties.

Therapeutic Uses of Эндокалцин

Therapeutic Uses and Key Benefits of Эндокалцин

This medication is applied across domains where additional symptomatic support is needed in the context of metabolic bone health. The therapeutic scope includes conditions presenting with systemic or localized discomfort, such as Postmenopausal Osteoporosis, Paget's Disease of the Bone, and Hypercalcemia (pathologically high blood calcium levels).

The medication may be applied in situations involving certain distressing symptoms to help ease the symptom burden. It is used to address symptom clusters that may become intense or disruptive, such as severe, sudden-onset bone pain resulting from recent osteoporotic vertebral compression fractures.

“It is commonly used when short-term symptomatic assistance is needed to address acute pain or manage temporary physiological imbalance.”

The benefit contributes to the improved day-to-day comfort during symptomatic periods and assists with maintaining functional stability, relevant when symptoms related to high blood calcium interfere with routine activities.

Quick Fact: Symptomatic Support for Acute Pain
Symptom addressed Severe pain related to recent vertebral compression fractures.
Clinical Scenario Applied during phases when symptoms become more noticeable and supportive relief is needed.
Patient Support Provides supportive relief that helps patients cope more steadily during difficult episodes.

Regulatory References

  1. NIH NCBI StatPearls

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Эндокалцин

The eligibility profile for Эндокалцин (Calcitonin Salmon) is strictly defined by government regulatory documents, outlining populations who are prohibited, restricted, or permitted to use the medicine.


Contraindicated Populations

Use is strictly contraindicated in patients with a known history of Hypersensitivity to the active ingredient or its excipients. It is also prohibited in individuals with Hypocalcemia (low blood calcium levels), which must be corrected before treatment initiation. The medicine is contraindicated for pregnant women and nursing mothers (lactation).


Age and Use Restrictions

Эндокалцин is only established for use in adults 18 years and older. It is not recommended for use in children and adolescents (under 18 years), as safety and efficacy data have not been established in this age group. Patients with renal impairment may require special consideration.


Conditional and Duration Limits

A major regulatory constraint for all eligible adults is that treatment must be limited to the shortest possible duration. Eligibility for certain conditions, such as postmenopausal osteoporosis, is often restricted to patients for whom alternative treatments are unsuitable or contraindicated. Additionally, use requires that any pre-existing untreated disorders of mineral metabolism are addressed prior to starting therapy.

What should I know about interactions with other medicines?

The official regulatory documents for Эндокалцин (Calcitonin Salmon) detail its known interaction profile, which is largely established by its influence on systemic electrolyte balance and renal excretion. The label notes that systematic drug interaction studies have generally not been performed.

Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with Lithium is documented to result in a reduction in its plasma concentrations. This reduction occurs because Эндокалцин formally increases the urinary clearance of Lithium. This clearance mechanism necessitates caution when combining the medicines.

For pharmacodynamic interactions, caution is advised with Cardiac Glycosides and Calcium Channel Blocking Agents. Their therapeutic effects may be modified due to documented changes in cellular electrolyte concentrations caused by Эндокалцин. Furthermore, combining this medicine with Bisphosphonates carries the risk of an additive calcium-lowering effect (hypocalcemia).

Contextual Restrictions

No specific interactions are formally documented with food, alcohol, or herbal products for the nasal spray or injection formulations. A population-specific note observes that prior use of diphosphonates in patients with Paget’s disease may reduce the anti-resorptive response to Calcitonin Salmon.

Mechanism of Action

How Эндокалцин Works

Targeted Recognition: The Selective Delivery System

The drug's specialized antibody component selectively binds to a target antigen (protein) found on the surface of the intended cells. This precise molecular recognition acts as a delivery mechanism, causing the compound to be concentrated selectively at the target cell population.

Intracellular Activation and Payload Release

This mechanism involves the drug being absorbed into the cell (internalization) after binding to its target. Once inside, specific intracellular conditions cause the cytotoxic payload to be released. This controlled activation process restricts the activity of the active payload to the cellular interior, which defines the resulting physiological effect.

Inhibition of Cell Proliferation

This final domain describes how the released payload interferes directly with the cell's fundamental processes, such as microtubule assembly required for division. By arresting the cell cycle and triggering apoptosis (programmed cell death), the mechanism ultimately results in a selective change in the number of target cells within the system.

Dosage and Administration Information

How Эндокалцин is Used

Эндокалцин (Calcitonin Salmon) is administered by injection or intranasally (as a spray), with the route and dosing regimen determined by the specific condition being addressed.


Official Dosing and Administration

Condition Route of Administration Standard Adult Dose and Frequency
Postmenopausal Osteoporosis Intranasal 200 IU (one spray) once daily, alternating nostrils.
Subcutaneous (SC)/Intramuscular (IM) 100 IU daily or every other day.
Paget's Disease of Bone SC or IM Injection Initial: 100 IU once daily; Maintenance: May be reduced to 50 IU three times a week.
Hypercalcemia SC or IM Injection Starting: 4 IU/kg every 12 hours; Max: Up to 8 IU/kg every 6 hours.
Intravenous (IV) Infusion Up to 10 IU/kg in 500 mL saline over at least 6 hours, in emergency cases.

Key Instructions for Proper Use

  • Preparation: For the nasal spray, the device must be allowed to reach room temperature and be primed before the first dose. The spray should be administered into one nostril per day, alternating the nostril daily.
  • Duration: Treatment for Paget's Disease is typically a minimum of three months. For osteoporosis, the need for continued therapy should be re-evaluated periodically.
  • Supplementation: For use in osteoporosis and Paget's disease, patients must receive adequate intake of elemental calcium (at least 1000 mg/day) and Vitamin D (at least 400 IU/day).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Эндокалцин

Evidence for Use in Postmenopausal Osteoporosis

Research involves randomized controlled trials (RCTs) and long-term studies in postmenopausal women with osteoporosis. These studies monitored changes in bone mineral density (BMD) in the spine and tracked the occurrence rates of vertebral (spinal) fractures. Studies described patterns related to the occurrence rates of vertebral fractures in the observed groups. However, when research examined non-spinal fracture events, such as hip fractures, the findings were mixed and inconsistent across large-scale investigations. Certainty remains low for some of the long-term outcomes, and there is limited information regarding the prevention of non-spinal fractures.

Evidence for Use in Paget's Disease of the Bone

Clinical studies examined how the medicine influenced biological markers that indicate excessive bone turnover in patients with symptomatic Paget's disease. These outcomes were monitored alongside patient-reported outcomes describing perceived discomfort. Studies consistently reported a measurable shift in the activity of these bone turnover biomarkers. However, key limitations relate to treatment duration, as regulatory advice restricts its use to short periods only. Research also describes the potential for some patients to develop substances that can interfere with the medicine's influence over time.

Evidence for Acute Pain Relief and Hypercalcemia

Research was evaluated in two distinct acute situations: managing sudden, severe bone pain from recent spinal fractures and stabilizing pathologically high blood calcium levels. For acute pain, research provides insight into short-term changes, but evidence is limited to the acute phase and did not support its use in managing chronic or long-standing bone pain. For hypercalcemia, the studies monitored the speed and extent of lowering elevated blood calcium levels, with data showing patterns related to a rapid physiological response when it was studied in settings involving temporary physiological imbalance. This research is strictly limited to acute emergency settings.

The Landscape of Evidence Gaps and Uncertainty

The overall research landscape indicates that follow-up durations were limited for many uses. Comparative evidence is lacking for long-term use in osteoporosis, and certainty remains low for fracture prevention. Subgroup findings are uncertain, meaning results apply only to the populations studied. The evidence highlights what is known — and what is still uncertain.

Key Studies & References

  1. Efficacy of calcitonin for treating acute pain associated with osteoporotic vertebral compression fracture: an updated systematic review
  2. Calcitonin salmon injection USP prescribing information (Cipla USA)

Frequently Asked Questions (FAQ)

Common questions about Эндокалцин (FAQ)

Q: Can I take Эндокалцин with my blood pressure medication?

A: Official regulatory documents note that caution is advised when Эндокалцин is combined with certain heart or blood pressure medicines. Specifically, this includes Cardiac Glycosides and Calcium Channel Blocking Agents. This is because the medicine may cause changes in cellular electrolyte concentrations, which could modify the effects of those specific drugs.

Q: Does Эндокалцин interact with common pain relievers like ibuprofen?

A: The official documentation states that systematic drug interaction studies have generally not been performed. As such, specific interactions with common non-prescription pain relievers, such as ibuprofen, are not formally documented in the official interaction profile.

Q: Can Эндокалцин cause changes in mood or sleep?

A: Officially documented adverse reactions include effects classified under Nervous System Disorders, such as dizziness and headache. Furthermore, psychiatric side effects, including depression, have been reported in studies. Should unexpected changes occur, consultation with a healthcare professional is consistent with official guidance.

Q: Can I use Эндокалцин if I have a history of kidney stones?

A: Official eligibility instructions state that any pre-existing untreated disorders of mineral metabolism must be addressed before starting treatment. This is because the medicine works by regulating calcium and bone metabolism. Use requires that any pre-existing untreated disorders of mineral metabolism be addressed, as stated in the regulatory documentation.

Q: Is Эндокалцин a vitamin or a mineral supplement?

A: Эндокалцин is officially classified as a prescription medication that falls under the category of Calcium-Regulating Hormone and Agents. It is a synthetic peptide hormone analog, meaning it is manufactured to mimic a naturally occurring hormone. It is not considered a standard vitamin or a mineral supplement.

Q: How is Эндокалцин different from regular calcium supplements?

A: Official documents describe Эндокалцин as a synthetic peptide hormone analog that acts to stabilize bone structure and manage calcium levels. This is different from standard elemental calcium supplements, which simply provide the mineral itself. In fact, regulatory instructions often require patients using this medicine for certain conditions to also take adequate amounts of elemental calcium and Vitamin D.

Q: Why do doctors prescribe Эндокалцин instead of other similar products?

A: Regulatory documents state that eligibility for certain conditions, such as postmenopausal osteoporosis, is often restricted to patients for whom alternative treatments are unsuitable or contraindicated. The restriction noted in regulatory documents is an indication that the medicine is reserved for specific patient populations.

Q: Is Эндокалцин available over the counter?

A: No. Official classification documents define Эндокалцин as a prescription medication.

Q: Does Эндокалцин require a prescription in my country?

A: Yes, official regulatory classifications define Эндокалцин as a prescription medication.

Q: How quickly does Эндокалцин start working?

A: For acute uses, such as for high calcium levels (hypercalcemia) or acute pain, research has described patterns related to a rapid physiological response. However, for long-term conditions like osteoporosis, the time needed to observe the full therapeutic effects of the medicine is not described as immediate.

Q: How long do most people need to take Эндокалцин?

A: Regulatory advice states that treatment must be limited to the shortest possible duration due to safety concerns associated with long-term use. For Paget's disease, treatment is typically a minimum of three months. For osteoporosis, the need for continued therapy should be re-evaluated periodically as advised in the official instructions.

Q: Can Эндокалцин cause stomach upset or digestive issues?

A: Yes, Gastrointestinal Disorders are common side effects noted in regulatory documents. Nausea and vomiting are classified as 'Very Common', and diarrhea is classified as 'Common'. Nausea and vomiting are often more pronounced upon starting therapy and may diminish with continued use.

Q: Are there common side effects I should be aware of when using Эндокалцин?

A: Commonly reported adverse reactions include nausea, vomiting, and facial or upper body flushing. Other common effects include dizziness, headache, diarrhea, and pain in the muscles or joints (musculoskeletal pain). Serious, though very rare, allergic reactions are also noted in the safety profile.

Q: Are there any specific foods or drinks that interact with Эндокалцин?

A: The official regulatory label notes that no specific interactions are formally documented with food, alcohol, or herbal products for the injection or nasal spray formulations. However, for certain conditions, adequate intake of calcium and Vitamin D is required.

Q: Is it safe to drink alcohol while taking Эндокалцин?

A: The official regulatory label notes that no specific interactions are formally documented with food, alcohol, or herbal products for the injection or nasal spray formulations.

Q: What is the evidence that Эндокалцин helps with its described use?

A: Evidence described in official studies covers several areas. For osteoporosis, research examined patterns related to bone mineral density changes and vertebral fracture rates. For Paget's disease, studies consistently showed measurable shifts in bone turnover biomarkers. For hypercalcemia, data showed patterns related to a rapid physiological response in acute settings.

Q: Have there been recent clinical studies on Эндокалцин?

A: The official overview of evidence references multiple study types, including randomized controlled trials (RCTs) and long-term investigations examining effects and safety. This suggests ongoing or recently evaluated data, though follow-up durations were noted as limited for many uses.

Q: Is Эндокалцин considered a long-term treatment?

A: Regulatory constraints advise that treatment must be limited to the shortest possible duration. Furthermore, the official research overview indicates that follow-up durations were limited for many uses, especially for comparative long-term outcomes.

Q: Why do some people say Эндокалцин is hard to absorb?

A: The active component is a synthetic peptide hormone analog. This type of molecule is formulated into injection and nasal spray dosage forms, as noted in official documents, to enable its absorption.

Q: Is the absorption rate of Эндокалцин better than other supplements?

A: The core component is a synthetic peptide hormone analog manufactured to exhibit greater potency and a longer biological half-life when compared to the human calcitonin molecule. This characteristic is related to its classification as a synthetic hormone analog.

Q: Is it possible to be allergic to Эндокалцин?

A: Yes, official safety documentation notes that use is contraindicated (prohibited) in patients with a known history of hypersensitivity to the active ingredient. Additionally, serious allergic reactions, including anaphylactic shock, have been documented as a rare but possible adverse reaction.

Q: What should I do if I miss a dose of Эндокалцин?

A: Official instructions advise that the missed dose be applied as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule continued. A double dose should not be used to make up for a missed one.

Q: Is Эндокалцин a generic drug?

A: The active ingredient in the medicine is the generic chemical name Calcitonin Salmon (Кальцитонин лосося). This substance is classified within the pharmaceutical group known as Calcitonin preparations.

Q: Is Эндокалцин a new or an established medication?

A: The drug's official classification via the ATC code (H05BA01) and its regulatory licensing history indicate that it is an established medicine.

Q: Can I take other calcium supplements while on Эндокалцин?

A: Yes, for its use in osteoporosis and Paget's disease, regulatory instructions specify the need for adequate intake of both elemental calcium (at least 1000 mg/day) and Vitamin D (at least 400 IU/day). This means standard calcium supplementation is often required alongside the medication.

Q: Does taking Эндокалцин require regular blood tests?

A: Official documentation advises that patients with certain pre-existing mineral metabolism disorders or known hypocalcemia (low blood calcium) should be monitored during therapy. This monitoring typically involves checking serum calcium levels to ensure the medicine is affecting the body as intended and to avoid safety concerns.

Q: What is the shelf life of Эндокалцин?

A: For the injectable solution, the official shelf life is typically 5 years when stored in the refrigerator and protected from freezing, as specified by the manufacturer's official instructions.

Q: Are there reports of long-term users having specific issues with Эндокалцин?

A: Yes, official safety documentation notes an increased risk of malignancy (cancer) associated with long-term use. This finding has prompted regulatory authorities to advise duration limitations for its use.

Q: Why might a doctor switch me from another supplement to Эндокалцин?

A: Regulatory documents note that eligibility for certain conditions is often restricted to patients for whom alternative treatments are unsuitable or contraindicated. This restriction is an indication that the medicine is reserved for specific patient populations for whom other treatments are unsuitable or contraindicated.

Q: Does the time of day I take Эндокалцин matter?

A: Official guidance advises users to take the medication around the same time every day to help maintain a regular dosing schedule. The key is consistency in administration time.

Q: Do I need to change my diet while taking Эндокалцин?

A: For its use in osteoporosis and Paget's disease, regulatory instructions specify the need for adequate daily intake of both elemental calcium and Vitamin D. Therefore, dietary adjustments or supplementation are often necessary to meet these requirements.

Q: Is it common for people to switch from injectables to oral Эндокалцин?

A: The dosage forms officially documented are solutions for injection (subcutaneous or intramuscular) and nasal solution (spray). Oral forms are not authorized for use.

Q: Does Эндокалцин help with muscle cramps?

A: The primary general purpose is defined as bone density conservation and calcium level management. Muscle cramps are not listed as a primary use, but rather as a symptom of a possible adverse reaction, hypocalcemia (low blood calcium), which is an officially noted safety concern.

Q: Can I take Эндокалцин if I am vegetarian or vegan?

A: The active ingredient is Calcitonin Salmon (Кальцитонин лосося). This is a synthetic peptide analog derived from the salmon species hormone, which means it is not fully plant-based in origin.

How should Эндокалцин be stored and disposed of?

To ensure the effectiveness and safety of Эндокалцин, always follow the specific storage instructions printed on the official package label or provided by a healthcare professional. Most medications require storage at controlled room temperature, away from excessive moisture, heat, or direct light.

Always store this medication out of the sight and reach of children and pets to prevent accidental ingestion.

Check the label for any specific stability requirements, such as rules for refrigeration, protection from freezing, or how long the product can be used after opening or preparation.

When disposing of unused or expired Эндокалцин, do not flush it down a toilet or pour it into a drain unless explicitly instructed to do so. Instead, follow local governmental regulations or consult your pharmacist regarding a safe medication take-back program. Disposal must protect the environment and prevent accidental exposure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Эндокалцин found in:

A-Z Index: